Immune hyporeactivity to bacteria and multiple TLR-ligands, yet no response to checkpoint inhibition in patients just after meeting Sepsis-3 criteria

PLoS One. 2022 Aug 18;17(8):e0273247. doi: 10.1371/journal.pone.0273247. eCollection 2022.

Abstract

Rationale: The immune profile of sepsis patients is incompletely understood and hyperinflammation and hypoinflammation may occur concurrently or sequentially. Immune checkpoint inhibition (ICI) may counter hypoinflammation but effects are uncertain. We tested the reactivity of septic whole blood to bacteria, Toll-like receptor (TLR) ligands and to ICI.

Methods: Whole blood assays of 61 patients' samples within 24h of meeting sepsis-3 criteria and 12 age and sex-matched healthy volunteers. Measurements included pattern/danger-associated molecular pattern (P/DAMP), cytokine concentrations at baseline and in response to TLR 2, 4, and 7/8 ligands, heat-inactivated Staphylococcus aureus or Escherichia coli, E.coli lipopolysaccharide (LPS), concentration of soluble and cellular immune checkpoint molecules, and cytokine concentrations in response to ICI directed against programmed-death receptor 1 (PD1), PD1-ligand 1, or cytotoxic T-lymphocyte antigen 4, both in the absence and presence of LPS.

Main results: In sepsis, concentrations of P/DAMPs and inflammatory cytokines were increased and the latter increased further upon incubation ex vivo. However, cytokine responses to TLR 2, 4, and 7/8 ligands, heat-inactivated S. aureus or E. coli, and E. coli LPS were all depressed. Depression of the response to LPS was associated with increased in-hospital mortality. Despite increased PD-1 expression on monocytes and T-cells, and monocyte CTLA-4 expression, however, addition of corresponding checkpoint inhibitors to assays failed to increase inflammatory cytokine concentrations in the absence and presence of LPS.

Conclusion: Patients first meeting Sepsis-3 criteria reveal 1) depressed responses to multiple TLR-ligands, bacteria, and bacterial LPS, despite concomitant inflammation, but 2) no response to immune checkpoint inhibition.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cytokines / metabolism
  • Escherichia coli / metabolism
  • Humans
  • Immune Checkpoint Inhibitors
  • Ligands
  • Lipopolysaccharides
  • Monocytes / metabolism
  • Sepsis* / metabolism
  • Staphylococcus aureus / metabolism
  • Toll-Like Receptor 2* / metabolism
  • Toll-Like Receptors / metabolism

Substances

  • Cytokines
  • Immune Checkpoint Inhibitors
  • Ligands
  • Lipopolysaccharides
  • Toll-Like Receptor 2
  • Toll-Like Receptors

Grants and funding

A.B. - D/107-40930 - IFORES program of the medical faculty, Universität Duisburg-Essen - https://www.uni-due.de/med/forschung/forschungsfoerderung/ifores-programm W.B. - ELAN scholarship - no funding ID - Else-Kröner-Fresenius-Stiftung via the medical faculty, Universität Duisburg-Essen - https://www.uni-due.de/med/promotionskolleg/ | https://www.ekfs.de/ The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.